Key result
Anti-angiogenic therapy with bevacizumab and the platelet-derived growth factor receptor antagonist imatinib have shown promise in managing pulmonary tumor thrombotic microangiopathy.
Why the study?
Pulmonary tumor thrombotic microangiopathy is a rare, poor-prognosis paraneoplastic syndrome that causes acute or subacute pulmonary heart failure and mimics other pulmonary diseases, necessitating a review of treatment strategies.
PTTM is a rare, rapidly fatal paraneoplastic syndrome causing severe pulmonary hypertension, for which early recognition and targeted therapies like bevacizumab and imatinib may offer symptomatic improvement.
Emphasizes early PTTM recognition in adenocarcinoma patients with acute PAH; leaves open targeted therapies beyond supportive care.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare paraneoplastic syndrome associated with various adenocarcinomas, most commonly gastric adenocarcinoma. This condition can progressively worsen pulmonary arterial hypertension, leading to acute or subacute pulmonary heart failure and respiratory insufficiency. This paper examines the pathogenesis, clinical presentation, diagnosis, treatment, and prognosis of PTTM. Given PTTM's poor prognosis, we emphasize treatment strategies. PTTM in adenocarcinoma patients can mimic other pulmonary diseases, causing diagnostic delays. Current PTTM treatment strategies primarily focus on managing the underlying malignancy and addressing thrombotic complications. Anti-angiogenic therapy with bevacizumab and the platelet-derived growth factor receptor antagonist imatinib have shown promise in multiple cases. Further research is needed to develop more effective and targeted therapies for this challenging condition. The precise mechanisms underlying this association remain to be fully elucidated.
No takes yet. Share an insight, caveat, or question.
Gayibov et al. (2025) conducted a review in Pulmonary tumor thrombotic microangiopathy (PTTM) associated with adenocarcinoma. Targeted therapies (bevacizumab and imatinib) was evaluated. Anti-angiogenic therapy with bevacizumab and the platelet-derived growth factor receptor antagonist imatinib have shown promise in managing pulmonary tumor thrombotic microangiopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: